Thiazolidinediones

Endocrinology and Metabolism Clinics of North America

Volumn 26, Issue 3, 1997, Pages 553-573

  Henry, R R ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; ENGLITAZONE; GLIBENCLAMIDE; GLUCOSE; GLUCOSE TRANSPORTER; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL; TROGLITAZONE;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GLUCOSE TOLERANCE; GLYCOGEN STORAGE DISEASE TYPE 1; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN SENSITIVITY; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALIA;

EID: 0030751488     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70267-X     Document Type: Article

References (59)

1. T. Antonucci R. Whitcomb R. McLain Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone Diabetes Care 20 1997 188 193
2. M. Bahr M. Spelleken M. Bock Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes Diabetologia 39 1996 766 774
3. K. Berkowitz R. Peters K.L. Kjos Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM Diabetes 45 1996 1572 1579
4. T.A. Buchanan W.P. Meehan Y.Y. Jeng Blood pressure lowering by pioglitazone: Evidence for a direct bascular effect J Clin Invest 96 1995 354 360
5. T.P. Ciaraldi A. Gilmore J.M. Olefsky In vitro studies on the action of CS-045, a new antidiabetic agent Metabolism 39 1990 1056 1062
6. T.P. Ciaraldi K. Huber-Knudsen M. Hickman Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents Metabolism 44 1995 976 982
7. R.A. DeFronzo R.C. Bonadonna E. Ferrannini Pathogenesis of NIDDM: A balanced overview Diabetes Care 15 1992 318 368
8. P. De Vos A.-M. Lefebvre S.G. Miller Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ J Clin Invest 98 1996 1004 1009
9. A. Dunaif D. Scott D. Finegood The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome J Clin Endocrinol Metab 81 1996 3299 3306
10. T. Fujita Y. Sugiyama S. Taketomi Reduction of insulin resistance in obese and/or diabetic animals by 3[-4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3870, U-63,287,ciglitazone), a new antidiabetic agent Diabetes 32 1983 804 810
11. T. Fujiwara A. Okuno S. Yoshioka Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice Metabolism 44 1995 486 490
12. T. Fujiwara M. Wade K. Fukuda Characterization of CS-045, a new oral antidiabetic agent. II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/Ksj-db/db/mice Metabolism 40 1991 1213 1218
13. T. Fujiwara S. Yoshioka T. Yoshioka Characterization of new oral antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats Diabetes 37 1988 1549 1558
14. J.-P. Fulgencio C. Kohl J. Girard Troglitazone inhibits fatty acid oxidation and esterification, and gluconeogenesis in isolated hepatocytes from starved rats Diabetes 45 1996 1556 1562
15. M. Ghazzi C. Balagtas J. Perez Treatment of NIDDM patients with troglitazone is not associated with increased cardiac mass or impaired cardiac function Diabetes 44 suppl 1 1995 157A
16. Horikoshi H, Fujiwara T, Shimada M, et al: Suppression of hepatic gluconeogenesis by CS-045 in KK mice and in perfused liver. [abstract]. Diabetes 39 (suppl 1):111A,
17. H. Horikoshi A. Okuno T. Fujiwara Peripheral effects of a new antidiabetic agent, CS-045: Acute stimulation of insulin-induced glucose uptake in perfused rat hindlimb Diabetes 42 suppl 1 1993 59A
18. Y. Inoue K. Tanigawa S. Nakamura Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats Diabetes Res Clin Pract 27 1995 19 26
19. Y. Iwamoto K. Kosaka T. Kuzuya Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy Diabetes Care 19 1996 151 156
20. Y. Iwamoto I. Shiraishi T. Kuzuya Effect of CS-045 treatment on serum proinsulin level in NIDDM patients Diabetes 42 suppl 1 1993 57A
21. Kawai K, Okada T, Komai T: Metabolism of a novel antidiabetic drug, CS-045 (II). Pharmacokinetic study on sulfuric acid and glucuronic acid conjugates of CS-045 [abstract 30V 3-031]. Presented at the 11th Annual Meeting of the Pharmaceutical Society of Japan, Tokyo, March 28 to 30, 1991
22. M. Kellerer G. Kroder S. Tippmer Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts Diabetes 43 1994 447 453
23. G. Kroder B. Bossenmaier M. Kellerer Tumor necrosis factor-α- and hyperglycemia-induced insulin resistance: Evidence for different mechanisms and different effects on insulin signaling J Clin Invest 97 1996 1471 1477
24. S. Kumar A.J.M. Boulton H. Beck-Nielsen Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients Diabetologia 39 1996 701 709
25. R.E. Law W.P. Meehan X.-P. Xi Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia J Clin Invest 98 1996 1897 1905
26. M.-K. Lee J.M. Olefsky Acute effects of troglitazone on in vivo insulin action in normal rats Metabolism 44 1995 1166 1169
27. T. Lemberger B. Desvergne W. Wahli Peroxisome proliferator-activated receptors: A nuclear receptor signaling pathway in lipid physiology Annu Rev Cell Dev Biol 12 1996 335 363
28. W.W. Li T. Leff Regulation of hepatic glucokinase gene transcription by troglitazone Diabetes 44 suppl 1 1995 46A
29. H. Maegawa R. Ide M. Hasegawa Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities J Biol Chem 270 1995 7724 7730
30. K. Mimura F. Umeda S. Hiramatsu Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes Diabet Med 11 1994 685 691
31. K. Murano Y. Inoue M. Emoto CS-045, a new oral antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes Eur J Pharmacol 254 1995 257 262
32. N. Noguchi H. Sakai Y. Kato Inhibition of oxidation of low density lipoprotein by troglitazone Atherosclerosis 123 1996 227 234
33. J.J. Nolan B. Ludvik P. Beerdsen Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N Engl J Med 331 1994 1188 1193
34. R. Norris T. Valiquett C. Balagtas Comparison of troglitazone (CI991) dosing regimens and placebo in the treatment of patients with NIDDM Diabetes 42 suppl 1 1993 59A
35. T. Ogihara H. Rakugi H. Ikegami Antihypertensive effect of CS-045 (troglitazone), a new oral insulin action enhancer, in hypertensive patients with non–insulin-dependent diabetes mellitus Rinsho Iyaku 10 1994 1657 1669
36. T. Ogihara H. Rakugi H. Ikegami Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives Am J Hypertens 8 1995 316 320
37. J. Ohsumi S. Sakakibara J. Yamaguchi Troglitazone prevents the inhibitory effects of inflammatory cytokines on insulin-induced adipocyte differentiation in 3T3-L1 cells Endocrinology 135 1994 279 282
38. T. Onuma M. Tsutsui T. Goto Effect of CS-045 on glucose tolerance in patients with NIDDM Prog Med 10 1990 3207 3211
39. T. Onuma M. Tsutsui T. Goto The effect of a new oral hypoglycemic drug, CS-045, on glucose tolerance and serum lipids in nonobese Japanese patients with non–insulin-dependent diabetes mellitus: A pilot study Curr Ther Res 55 1994 416 421
40. G. Reaven Role of insulin resistance in human disease Diabetes 37 1988 1595 1607
41. Rezulin (Troglitazone) Package Insert 1997 Warner-Lambert Company Morris Plains, NJ
42. A.R. Saltiel J.M. Olefsky Thiazolidinediones in the treatment of insulin resistance in type II diabetes Diabetes 45 1996 1661 1669
43. H. Shibata S. Nii M. Kobayashi Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers: Safety and pharmacokinetics in single administration Rinsho Iyaku 9 1993 1503 1518
44. H. Shibata S. Nii M. Kobayashi Phase I study of a new hypoglycemic agent CS-045 in healthy volunteers: Safety and pharmacokinetics in repeated administration Rinsho Iyaku 9 1993 1519 1537
45. A. Shibukawa T. Sawada C. Nakao High-performance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and in human plasma J Chromatogr A 697 1995 337 343
46. M. Shimabukuro S. Higa T. Shinzato Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats Metabolism 45 1996 1168 1173
47. T. Sohda K. Mizuno E. Imamiya Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethylmethoxy)benzyl]thiozolidine-2,4-dione(ADD-3878) and its derivatives Chem Pharm Bull 30 1982 3580 3585
48. S.L. Suter J.J. Nolan P. Wallace Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects Diabetes Care 15 1992 193 203
49. D. Szalkowski S. White-Carrington J. Berger Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells Endocrinology 136 1995 1474 1481
50. S.R. Tafuri Troglitazone enhances differentiation, basal glucose uptake, and GLUT4 protein levels in 3T3-L1 adipocytes Endocrinology 137 1996 4706 4712
51. H. Takino S. Okuno S. Uotani Increased insulin responsiveness after CS-045 treatment in diabetes associated with Werner's syndrome Diabetes Res Clin Pract 24 1994 167 172
52. K. Tanigawa S. Ohguni Y. Kato Effect of CS-045 in a case of type IA glycogen storage disease complicated by diabetes mellitus Tonyobyo 37 1994 301 306
53. M. Tominaga M. Igarashi M. Daimon Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats Endocrine J 40 1993 343 349
54. T.R. Valiquett C.C. Balagtas R.W. Whitcomb Troglitazone dose-response study in patients with noninsulin-dependent diabetes. [abstract] Clin Res 42 1994 400A
55. T.M. Willson J.E. Cobb D.J. Cowan The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones J Med Chem 39 1996 665 668
56. M. Yano S. Okuno S. Uotani The effect of a new oral antihyperglycemic drug (CS-045) on insulin resistance in Werner's syndrome Int Congr Series Excerpta Med 997 1992 357 360
57. T. Yoshioka Y. Aizawa T. Fujita Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045 Chem Pharm Bull 39 1991 2124 2125
58. T. Yoshioka T. Fujita T. Kanai Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation J Med Chem 32 1989 421 428
59. S. Yoshioka H. Nishino T. Shiraki Antihypertensive effects of CS-045 treatment in obese Zucker rats Metabolism 42 1993 75 80